BioSpace News Archive

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief executive officer has been invited to present at the Re-Engaging Medical Practices in an Era of COVID-19 webinar, presented by Maxim Group and M-Vest on Thursday, July 16, 2020.

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock.

Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways, today announced the closing of an underwritten public offering of 6,900,000 shares of common stock at a public offering price of $26.00 per share, before underwriting discounts and commissions.

In a letter to the Centers for Medicare & Medicaid Services (CMS), The Joint Commission called on the agency to extend several waivers it enacted in response to the COVID-19 pandemic, including the removal of physician supervision for Certified Registered Nurse Anesthetists (CRNAs).

Breg, Inc., a leading orthopedic bracing and billing services company, has partnered with UK-based distributor Joint Operations LLP to expand delivery of its premium, high-value orthopedic products in the UK/Ireland market as of July 1, 2020.

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020.

Abbott (NYSE: ABT) announced today it has reached an agreement with Edwards Lifesciences Corporation to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has reached an agreement with Abbott to settle all outstanding patent disputes between the companies in cases related to transcatheter mitral and tricuspid repair products.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will discuss the company’s clinical programs in anterior and posterior ocular disease as part of the Ophthalmology Innovation Summit’s Virtual Public Company Showcase on Thursday, July 16, 2020

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the Fiscal Year Ended March 31, 2020.